Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys 4,328 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 188,369 shares of the company’s stock after acquiring an additional 4,328 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Teva Pharmaceutical Industries were worth $4,152,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TEVA. Wilmington Savings Fund Society FSB acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $50,000. Ameliora Wealth Management Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $66,000. IFP Advisors Inc grew its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $104,000. Finally, Assetmark Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,370.3% during the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after purchasing an additional 4,851 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Finally, Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock opened at $16.18 on Monday. The firm has a fifty day moving average of $17.79 and a two-hundred day moving average of $18.21. The stock has a market capitalization of $18.34 billion, a price-to-earnings ratio of -11.16, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.